EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE PSA AND INADEQUATE RESPONSE TO BIOLOGIC DMARDS (SELECT-PSA-2): A DOUBLE-BLIND, RANDOMISED CONTROLLED PHASE III TRIAL Genovese, M. C., Lertratanakul, A., Anderson, J., Papp, K., Tillett, W., van den Bosch, F., Tsuji, S., Dokoupilova, E., Keiserman, M., Wang, X., Zhong, S., Zueger, P., Pangan, A., Mease, P. OXFORD UNIV PRESS. 2021: 90

View details for DOI 10.1093/rheumatology/keab247.166

View details for Web of Science ID 000667796000199